GlassScriptPhysician profile
Joseph S Buckley
NPI 1710984877
$6,565.38
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $1,618 · 2021: $2,641 · 2022: $294 · 2023: $25.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.98 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,505.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $919.67 | 2019-2022 | |
| Janssen Biotech, INC. | $396.39 | 2019-2022 | |
| Gilead Sciences, INC. | $390.76 | 2019-2021 | |
| Redhill Biopharma INC. | $213.05 | 2020-2021 | |
| Ucb, INC. | $210.13 | 2019-2020 | |
| Pfizer INC. | $189.30 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $132.79 | 2020-2021 | |
| Shire North American Group INC | $122.18 | 2019 | |
| Merck Sharp & Dohme LLC | $90.65 | 2019-2021 | |
| Daiichi Sankyo INC. | $71.50 | 2022-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $64.46 | 2019-2021 | |
| Romark Laboratories, Lc | $63.72 | 2020 | |
| Nestle Healthcare Nutrition INC. | $62.12 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $57.21 | 2021 | |
| Braintree Laboratories, INC. | $52.45 | 2021 | |
| Concordia Pharmaceuticals INC. | $39.37 | 2019 | |
| Allergan, INC. | $33.51 | 2020 | |
| Qol Medical, LLC | $32.27 | 2019 | |
| Intercept Pharmaceuticals, INC. | $27.92 | 2020 | |
| Alnylam Pharmaceuticals INC. | $25.37 | 2020 | |
| Eisai INC. | $24.38 | 2020 | |
| Tersera Therapeutics LLC | $23.46 | 2021 | |
| Genzyme Corporation | $21.62 | 2021 | |
| Oxford Immunotec USA INC | $19.71 | 2021 | |
| Boston Scientific Corporation | $11.72 | 2019 | |
| Dova Pharmaceuticals | $11.47 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $9.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,048.57 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Buckley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.